Olema Pharmaceuticals Files 8-K
Ticker: OLMA · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1750284
| Field | Detail |
|---|---|
| Company | Olema Pharmaceuticals, INC. (OLMA) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, financials, disclosure
TL;DR
Olema Pharma filed an 8-K on Jan 10, 2025, for unregistered equity sales & financials.
AI Summary
Olema Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting unregistered sales of equity securities and filing financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in San Francisco, CA, operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates potential equity transactions and the submission of financial documents, which could impact investor understanding of the company's financial health and operational activities.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of unregistered equity sales and financial statements, not indicating immediate significant financial distress or major corporate events.
Key Numbers
- 001-39712 — Commission File Number (SEC File Number for Olema Pharmaceuticals)
- 30-0409740 — IRS Employer Identification No. (Tax identification for Olema Pharmaceuticals)
Key Players & Entities
- Olema Pharmaceuticals, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 780 Brannan Street, San Francisco, CA 94103 (address) — Principal Executive Offices
- 415 651-3316 (phone_number) — Registrant's Telephone Number
FAQ
What specific type of equity securities were sold in the unregistered offering?
The filing does not specify the type of equity securities sold in the unregistered offering.
Were these unregistered sales made to accredited investors?
The filing mentions 'Unregistered Sales of Equity Securities' but does not provide details on the nature of the purchasers.
What is the purpose of filing financial statements and exhibits with this 8-K?
The filing indicates that financial statements and exhibits are being submitted as part of the report, but the specific purpose or content is not detailed in the provided text.
Does the 8-K filing indicate any changes to Olema Pharmaceuticals' principal executive offices?
No, the filing lists the current principal executive offices as 780 Brannan Street, San Francisco, CA 94103, and does not mention any changes.
What is the SIC code for Olema Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Olema Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 948 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2025-01-10 16:01:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share OLMA The Nasdaq Global Se
Filing Documents
- d915597d8k.htm (8-K) — 27KB
- d915597dex41.htm (EX-4.1) — 86KB
- g915597g14b44.jpg (GRAPHIC) — 9KB
- 0001193125-25-004427.txt ( ) — 263KB
- olma-20250110.xsd (EX-101.SCH) — 3KB
- olma-20250110_lab.xml (EX-101.LAB) — 17KB
- olma-20250110_pre.xml (EX-101.PRE) — 11KB
- d915597d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 10, 2025 By: /s/ Shane Kovacs Shane Kovacs Chief Operating and Financial Officer